相似文献
1
Lobelane analogues as novel ligands for the vesicular monoamine transporter-2.
Bioorg Med Chem. 2005 Jun 2;13(12):3899-909. doi: 10.1016/j.bmc.2005.04.013.
2
Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.
J Med Chem. 2005 Aug 25;48(17):5551-60. doi: 10.1021/jm0501228.
3
Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
J Pharmacol Exp Ther. 2010 Feb;332(2):612-21. doi: 10.1124/jpet.109.160275. Epub 2009 Oct 23.
4
Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
J Pharmacol Exp Ther. 2004 Sep;310(3):1035-45. doi: 10.1124/jpet.104.068098. Epub 2004 Apr 30.
5
Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2.
Bioorg Med Chem Lett. 2008 Dec 15;18(24):6509-12. doi: 10.1016/j.bmcl.2008.10.042. Epub 2008 Oct 14.
6
Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
J Pharmacol Exp Ther. 2011 Oct;339(1):286-97. doi: 10.1124/jpet.111.184770. Epub 2011 Jul 21.
7
Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
Bioorg Med Chem Lett. 2016 May 15;26(10):2422-2427. doi: 10.1016/j.bmcl.2016.03.119. Epub 2016 Apr 1.
8
Quinlobelane: a water-soluble lobelane analogue and inhibitor of VMAT2.
Bioorg Med Chem Lett. 2010 Jun 15;20(12):3584-7. doi: 10.1016/j.bmcl.2010.04.117. Epub 2010 May 4.
9
Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.
J Pharmacol Exp Ther. 2011 Mar;336(3):724-33. doi: 10.1124/jpet.110.172882. Epub 2010 Sep 28.
10
Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
Bioorg Med Chem Lett. 2015 Jul 1;25(13):2613-6. doi: 10.1016/j.bmcl.2015.04.105. Epub 2015 May 9.
引用本文的文献
1
GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2.
Eur J Pharmacol. 2017 Jan 15;795:143-149. doi: 10.1016/j.ejphar.2016.12.016. Epub 2016 Dec 13.
2
1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2.
Bioorg Med Chem Lett. 2016 Jul 1;26(13):2997-3000. doi: 10.1016/j.bmcl.2016.05.025. Epub 2016 May 10.
3
Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
Bioorg Med Chem Lett. 2016 May 15;26(10):2422-2427. doi: 10.1016/j.bmcl.2016.03.119. Epub 2016 Apr 1.
4
Synthesis of Lobeline, Lobelane and their Analogues. A Review.
Org Prep Proced Int. 2015;47(5):317-337. doi: 10.1080/00304948.2015.1066642. Epub 2015 Aug 17.
5
The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.
Adv Pharmacol. 2014;69:71-106. doi: 10.1016/B978-0-12-420118-7.00002-0.
6
Synthesis of symmetrical 1,5-disubstituted granatanines.
Tetrahedron Lett. 2008 Oct 27;49(44):6330-6333. doi: 10.1016/j.tetlet.2008.08.066.
7
Exploring the effect of -substitution in -lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.
Medchemcomm. 2013 Mar;4(3):564-568. doi: 10.1039/C3MD20374C.
8
Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
J Pharmacol Exp Ther. 2011 Oct;339(1):286-97. doi: 10.1124/jpet.111.184770. Epub 2011 Jul 21.
9
Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.
Curr Top Med Chem. 2011;11(9):1103-27. doi: 10.2174/156802611795371332.
10
Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.
J Pharmacol Exp Ther. 2011 Mar;336(3):724-33. doi: 10.1124/jpet.110.172882. Epub 2010 Sep 28.
本文引用的文献
1
Indirect trapping of the retroconjugate addition reaction intermediate involved in the epimerization of lobeline: application to the synthesis of (-)-sedamine.
J Org Chem. 2004 Nov 26;69(24):8514-7. doi: 10.1021/jo048848j.
2
Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
J Pharmacol Exp Ther. 2004 Sep;310(3):1035-45. doi: 10.1124/jpet.104.068098. Epub 2004 Apr 30.
3
Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review.
J Neuropsychiatry Clin Neurosci. 2003 Summer;15(3):317-25. doi: 10.1176/jnp.15.3.317.
4
Characterization of a series of 3-amino-2-phenylpropene derivatives as novel bovine chromaffin vesicular monoamine transporter inhibitors.
J Med Chem. 2003 Jun 19;46(13):2599-605. doi: 10.1021/jm030004p.
5
Rhodium-catalyzed addition of arylboronic acids to alkynyl aza-heteroaromatic compounds in water.
J Org Chem. 2003 Feb 7;68(3):762-9. doi: 10.1021/jo0205255.
6
Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats.
Pharmacol Biochem Behav. 2003 Jan;74(2):279-86. doi: 10.1016/s0091-3057(02)00996-6.
7
Lobeline does not serve as a reinforcer in rats.
Psychopharmacology (Berl). 2003 Feb;165(4):397-404. doi: 10.1007/s00213-002-1289-6. Epub 2002 Nov 30.
8
Brain reward circuitry: insights from unsensed incentives.
Neuron. 2002 Oct 10;36(2):229-40. doi: 10.1016/s0896-6273(02)00965-0.
9
A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.
Biochem Pharmacol. 2002 Jan 15;63(2):89-98. doi: 10.1016/s0006-2952(01)00899-1.
10
Lobeline attenuates d-methamphetamine self-administration in rats.
J Pharmacol Exp Ther. 2001 Jul;298(1):172-9.
Zotero 插件